Dublin, May 17, 2024 (GLOBE NEWSWIRE) -- The "Hypoparathyroidism - Market Insight, Epidemiology And Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.
The global hypoparathyroidism market faces a transformative phase as key market players and emerging therapies show promise in treating this rare endocrine disorder. Experts have released in-depth market insights and forecasts up to 2032, analyzing current treatment landscapes, emerging therapies, and their anticipated impact on future market dynamics.
Understanding Hypoparathyroidism
Characterized by low serum calcium and elevated serum phosphorus levels due to insufficient parathyroid hormone (PTH), hypoparathyroidism presents a significant therapeutic challenge. Commonly arising post-thyroidectomy, it also has nonsurgical causes including genetic conditions, autoimmune destruction, and mineral deficiencies. Untreated, it leads to symptoms ranging from tingling and muscle cramps to seizures and cognitive impairment.
Diagnostic and Treatment Advances
Clinical diagnosis has become more sophisticated, with thorough family histories and laboratory evaluations becoming standard. The treatment regimen focuses on normalizing calcium levels and mitigating kidney and bone complications via dietary changes, supplements, and, in complex cases, intravenous calcium administration. The US also saw the approval of NATPARA, a synthetic PTH, although its use was disrupted by a global recall due to manufacturing issues.
Emerging Therapies on the Horizon
The market eagerly anticipates novel treatments, such as once-daily TRANSCON PTH and CaSR antagonist encalecret, promising improved patient outcomes and quality of life. Such innovations aim to address both short- and long-term complications associated with the disease.
Market Trends and Outlook
Analysis reveals significant market expansion opportunities, particularly in the United States, with a market size of approximately USD 200 million in 2022. Vitamin D analogs are currently leading therapy in market share, yet the landscape may shift dramatically as new therapies emerge.
Impact of Discontinued and Upcoming Therapies
The discontinuation of NATPARA has re-emphasized the necessity for reliable and safe long-term treatments for hypoparathyroidism. The forecast period expects to see market changes in response to the evolving treatment and drug options.
Expert and Key Opinion Leader Insights
Industry experts from renowned institutions such as Oregon Health & Science University shed light on current treatment patterns, patient reliance on conventional therapies, and challenges to accessibility. These insights serve as a leeway to understand and predict patient and market trends.
In conclusion, the hypoparathyroidism market is set to witness notable developments over the next decade, offering hope and improved care to patients worldwide.
Company Coverage:
- Ascendis Pharma
- Amolyt Pharma
- Bridgebio
- Calcilytix Therapeutics
Hypoparathyroidism Insights
- Patient Population
- Therapeutic Approaches
- Market size of each therapy
- Hypoparathyroidism Market Size and Trends
- Existing Market Opportunity
Hypoparathyroidism Report Key Strengths
- Ten-year Forecast
- The 7MM Coverage
- Hypoparathyroidism Epidemiology Segmentation (Segmented by diagnosed prevalent cases, gender, age, type, and cause-specific Cases)
Key Cross Competition evaluating the marketed as well as emerging therapies
Hypoparathyroidism Report Assessment
- Current Treatment and Management Practices
- Unmet Needs
- Market Attractiveness
- Qualitative Analysis (SWOT, Conjoint Analysis)
Key Questions Answered
- Would there be any changes observed in the current treatment approach?
- Will there be any improvements in hypoparathyroidism management recommendations?
- Would research and development advances pave the way for future tests and therapies for hypoparathyroidism?
- Would the innovations in diagnostic tests of hypoparathyroidism space experience a significant impact and lead to a positive shift in the treatment landscape of hypoparathyroidism?
- What kind of uptake will the new therapies witness in the coming years in hypoparathyroidism patients?
For more information about this report visit https://www.researchandmarkets.com/r/al267v
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
